anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Two groups of women were recruited. First, the nulliparous group served as a control. The second group was women after their first vaginal delivery. Personal characteristics, anamnestic and delivery data were collected, and clinical examination, ultrasound (US) and magnetic resonance imaging (MRI) was performed. The number of women to reach significance in the study was 40/per group. The investigators did not expect a transfer of patients between the two groups. Volunteers were recruited from a general gynecological outpatient clinic. They were thoroughly informed and informed consent was provided.

In nulliparous women, all examinations (clinical, US, MRI) were performed only once. In women after vaginal delivery, first US was performed within 72h after childbirth, in order to detect LAM avulsion and exclude these women. In women without avulsion, 6 weeks after delivery, during a general postpartum checkup, the clinical evaluation of pelvic floor muscle contraction was performed. In those where the score is 0-3 the 3D US was performed to confirm no change of hiatal area during contraction. Those scans were recorded as investigated data. Those women underwent MRI within 4 months US images were obtained with a GE Voluson E10 system (General Electric Healthcare, Chicago, IL) by one investigator. US data acquisition was performed translabial as already described.9 Volumes were acquired at rest, during Valsalva and contraction. From acquired volume was assessed PVM avulsion, size of urogenital hiatus. Decrease of hiatal area at contraction proves muscle function. The assessment of US scans was performed off-line at axial plane using the 4D View v 2.1-5.0 software (GE Medical Systems) by two investigators blinded against all clinical data. MRI images were obtained with a 3-T scanner (AchievaTM, Philips Healthcare). MRI included coronal, axial, and sagittal proton density-weighted sequences performed at rest, Valsalva and contraction. Primary outcome evaluated by MRI will be the cross-sectional area of the PVM. The precise MRI technique was already defined by the group of DeLancey and is in detail described in recent publication.7 Evaluation was performed off-line by two investigators blinded against all clinical data using ImageJ software. Intra- and interobserver variability was calculated.
Septic cardiomyopathy is a secondary myocardial injury caused by sepsis. N6-methyl-adenosine (m6A) modification is involved in the pathological progression of septic cardiomyopathy; however, the pathological mechanism remains unclear. In this study, we identified the overall m6A modification pattern in septic myocardial injury and determined its potential interactions with differentially expressed genes (DEGs). A sepsis mouse model exhibiting septic symptoms and myocardial tissue damage was induced by lipopolysaccharide (LPS). LPS-induced septic myocardial tissues and control myocardial tissues were subjected to methylated RNA immunoprecipitation sequencing and RNA sequencing to screen for differentially expressed m6A peaks and DEGs. We identified 859 significantly m6A-modified genes in septic myocardial tissues, including 432 upregulated and 427 downregulated genes. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed to explore the biological importance of differentially expressed m6A methylated genes and DEGs. Differentially expressed m6A methylated genes were enriched in immune- and inflammation-related pathways. Conjoint analysis revealed co-expression of differentially expressed m6A genes and DEGs, including genes that were upregulated or downregulated and those showing opposite trends. High expression of m6A-related genes (WTAP and IGF2BP2), interleukin-17, and interleukin-17 pathway-related genes (MAPK11 and TRAF3IP2) was verified using reverse transcription-quantitative PCR. We confirmed the presence of m6A modification of the transcriptome and m6A-mediated gene expression in septic myocardial tissues.
The herbal food additive is in the form of a liquid cough syrup. It assists the normal function of the upper respiratory tract, the lungs and the bronchi. It also has beneficial effects on the oral cavity and throat while maintaining the normal condition of the mucos membrane. The food additive has an immunostimulating effect. It comprises equal parts of extracts of the following herbs: plantain leaves (Plantago Ianceolata), primula flowers ( Primula Officinalis), black elder flowers (Sambucus Nigra), thyme tips (Thymus vulgaris), and liquorice root (sweet root ) (Glycyrrhiza glabra) to which are added sweetener - sorbitol, acidity regulator - citric acid, preservatives - sodium benzoate and potassium sorbate, flavour - oregano oil, stabilizer - xanthan, colorant - caramel paint and water. 1 claim
The present invention relates to an immunogenic composition including a multivalent pneumococcal polysaccharide-protein conjugate. Each conjugate includes a capsular polysaccharide of a different pneumococcal serotype conjugated with a carrier protein. Particularly, the multivalent immunogenic composition includes each conjugate which including a capsular polysaccharide including a different serotype of a Streptococcus pneumoniae-derived capsular polysaccharide conjugated with a carrier protein, wherein the capsular polysaccharide includes: a) a capsular polysaccharide having at least one serotype selected from the group consisting of serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F; and b) a capsular polysaccharide having at least one serotype selected from the group consisting of serotypes 10A, 11A, 15B, 22F, 23A and 35B. The multivalent immunogenic composition can induce an immune response against more diverse serotypes as compared to existing PREVENAR 13. Particularly, while PREVENAR 13 is designed mainly against the serotypes occurring frequently in Europe and North America, the immunogenic composition according to the present invention has a high coverage not only to Europe and North America but also to Asia. Therefore, the immunogenic composition according to the present invention can be used advantageously for preventing pneumococcal diseases of infants, children and adults.
The patient is in supine lying. The head and neck of patient are held in the hands of the practitioner, and then a gentle traction of a pulling force is applied. Intermittent periods of traction can be applied, holding each position for about 10 seconds. Traction is usually applied at about 20-30 degrees of neck flexion.
Fungal infections are life-threatening opportunistic infections that have emerged as a major cause of morbidity and mortality in critically ill patients. Yeast infections,mainly Candida spp., remain much more frequent than mold infections. Among mold infections, Aspergillus spp. represent the most frequently isolated filamentous fungi in these circumstances .Candida species are the most common cause of nosocomial fungal infections and the fourth most common source of hospital-acquired infections. Candidiasis is an infection caused by Candida, mostly limited to the skin, nails and mucous membranes. However, it can cause serious systemic infections. Candidiasis is an opportunistic infection occurring in presence of predisposing factors like extensive and prolonged administration of broad-spectrum antimicrobials, corticosteroids, immunosuppressive agents and cytotoxic drugs, diabetes mellitus, HIV, chronic renal failure, haemodialysis, renal transplantation or indwelling urinary catheter.The pathogenicity of Candida spp. is related to a combination of microbial factors such as their ability to grow at 37°C, polymorphism, biofilm formation, hydrolytic enzyme secretion, and phenotypic switching. Candida species are identified by different phenotypic methods including examination of their morphological features, analysis of their ability of carbohydrates assimilation and/or fermentation, and their ability of assimilating different nitrogen compounds. Numerous antifungal classes are used to treat Candida infections; polyenes, azoles, echinocandins and allylamines. These antifungals are used with varying efficacy depending on the type, site of infection and the susceptibility of different Candida species. Azoles are the most frequently used antifungal drugs to treat Candida infections as they achieve high success rates even over short durations of therapy. However, resistance among previously susceptible Candida species has emerged following the expanded use of antifungal agents. Antifungal susceptibility testing methods including broth dilution, disk diffusion and E test are now available with species-specific breakpoints developed by The Clinical and Laboratory Standards Institute (CLSI) for multiple antifungal agents.
BACKGROUND: Acute myeloid leukemia (AML) is a prevalent hematologic malignancy characterized by a steady rise in morbidity and mortality rates over time. The upregulation of methyltransferase-like 14 (METTL14) expression in AML has been identified; however, its specific contributions to AML progression and underlying molecular mechanisms have yet to be elucidated.
METHOD: METTL14-bound mRNAs were predicted using bioinformatics methods, analyzed, and screened to identify T-complex protein 1 (TCP1). The regulatory impact of METTL14 on TCP1 was observed. TCP1 expression in AML clinical samples was assessed using quantitative real-time PCR and western blot analysis. The involvement of TCP1 in AML malignant progression was assessed through in vitro and in vivo functional assays. The String database was utilized for predicting proteins that interact with TCP1, while western blot assays and immunoprecipitation were employed to validate the associated signaling pathways.
RESULTS: METTL14 overexpression upregulates TCP1 expression in AML cells. AML patients exhibit high levels of TCP1 expression. Elevated TCP1 levels in HL60 and U937 cells in vitro lead to increased proliferation, migration, invasion, and inhibition of apoptosis, while in vivo, it accelerates AML proliferation and tumorigenesis. Mechanistically, METTL14 modulates AML progression by influencing TCP1 transcript stability via m6A methylation, thereby regulating TCP1 expression. Additionally, PPP2R2C potentially serves as a crucial functional target of TCP1 implicated in the malignant progression of AML.
CONCLUSION: Upregulation of TCP1 expression in AML through METTL14-mediated m6A modification accelerates the malignant progression of the disease. Therefore, targeting the m6A modification of TCP1 could be a potential therapeutic strategy to enhance the treatment of AML.
Current treatment guidelines for dyslipidemia focus on fasting lipid panels, specifically LDL cholesterol (LDL) but compliance has been shown to be poor. Therefore, focus has shifted to non-fasting measurements. However, there has been limited data in patients with type 2 diabetes and further study is needed to illuminate the lipid changes that occur in the non-fasting state. This observational study examines fasting and postprandial lipids in patients with type 2 diabetes using standard chemical analysis and NMR. For comparison, lipid panels will be obtained at baseline and 3 hours following a standard meal in 30 patients with type 2 diabetes. These measurements will then be analyzed based on current ATP III guidelines. We will investigate the degree to which the postprandial assessments agree with the fasting assessments and the agreement between LDL and the two alternative measures --- non-HDL and NMR-LDL.
BACKGROUND: The eukaryotic elongation factor, EEF1A2, has been identified as an oncogene in various solid tumors. Here, we have identified a novel function of EEF1A2 in angiogenesis.
METHODS: Chick chorioallantoic membrane, tubulogenesis, aortic ring, Matrigel plug, and skin wound healing assays established EEF1A2's role in angiogenesis.
RESULT: Higher EEF1A2 levels in breast cancer cells enhanced cell growth, movement, blood vessel function, and tubule formation in HUVECs, as confirmed by ex-ovo and in-vivo tests. The overexpression of EEF1A2 could be counteracted by Plitidepsin. Under normoxic conditions, EEF1A2 triggered HIF1A expression via ERK-Myc and mTOR signaling in TNBC and ER/PR positive cells. Hypoxia induced the expression of EEF1A2, leading to a positive feedback loop between EEF1A2 and HIF1A. Luciferase assay and EMSA confirmed HIF1A binding on the EEF1A2 promoter, which induced its transcription. RT-PCR and polysome profiling validated that EEF1A2 affected VEGF transcription and translation positively. This led to increased VEGF release from breast cancer cells, activating ERK and PI3K-AKT signaling in endothelial cells. Breast cancer tissues with elevated EEF1A2 showed higher microvessel density.
CONCLUSION: EEF1A2 exhibits angiogenic potential in both normoxic and hypoxic conditions, underscoring its dual role in promoting EMT and angiogenesis, rendering it a promising target for cancer therapy.
The invention discloses a cholesterol oxidase mutant with improved substrate specificity and its application and belongs to the technical field of enzyme engineering. The mutant is obtained by performing amino acids deletion on the basis of cholesterol oxidase of Rhodococcus sp. origin (previously classified and named Brevibacterium sp. DGCDC-82). The original cholesterol oxidase of Rhodococcus sp. origin has equal activity on four substrates: cholesterol, sitosterol, pregnenolol and cholestanol, while the mutant CODr-M1 of the invention has significant changes in substrate specificity, and has highest activity on pregnenolol, that is 5.3 times as high as the activity on cholesterol. The specificity of the cholesterol oxidase to the substrate pregnenolol is effectively improved by using a method of the invention.
The invention relates to a solution used for removing livestock and poultry summer-heat. The solution comprises the raw materials of, by weight: 10-20 parts of sodium chloride, 8-15 parts of potassium chloride, 25-35 parts of glucose, 2-5 parts of camphor, 8-15 parts of borneol, 10-20 parts of ethanol, and 15-30 parts of water. The active components of the solution are inorganic salts and traditional Chinese medicines or traditional Chinese medicine extracts. The traditional Chinese medicines can easily be degraded in bodies, and can easily be discharged. Therefore, no medicine residue is generated, such that defects of drug resistance of chemical synthesized medicines and malformation caused by medicine residue are overcome. The health-caring liquid is suitable for various livestock and poultry.
<P>PROBLEM TO BE SOLVED: To relax a cold sense in the moment of applying a fomentation, to prevent the deterioration of the adhesive strength and percutaneous pharmaceutical effects of the fomentation, to make a protective film easily peelable, to prevent mutual sticking of a fomentation drug layer after peeling the protective film and to make the fomentation easily applicable to a desired position.  <P>SOLUTION: The fomentation is composed of a supporting material, the fomentation drug layer applied thereon, the protective film laminated thereon and a cover part provided thereon. The cover part is joined or continuous to the protective film at one end of the fomentation or in a position bisecting the fomentation and has a pull-out part for pulling out the cover part and the protective film at the tip of the cover part. At least one layer having higher heat insulating properties than those of the protective film is present between the protective film and the outermost surface of the cover part. The cover part is pressed against an affected part and the pull-out part is pulled to thereby apply the fomentation to the affected part while pulling out the cover part and the protective film.  <P>COPYRIGHT: (C)2009,JPO&INPIT
A system and process generate a closed loop test and transactions which removes the variable of lack of data and verifies that each system in the network is indeed moving data instead of simply showing that the software in the network is running. In some embodiments, a unique digital imaging and communications in medicine (DICOM) image is generated. The image may be retrieved from each system in the network so that individual network elements are tested. A new DICOM image may in some embodiments be generated and sent to a first system and retrieved from a second system in the network verifying the integration between the two connected systems. The sum of these tests may automatically monitor all devices in the overall system. The process may be automated so that system administrators may be notified when there is a problem via for example, an electronic dashboard, email or SMS text message.
PURPOSE: In patients with traumatic, infectious, degenerative, and neoplastic surgical indications in the cervical spine, commonly the anterior approach is used. Often these patients require a tracheostomy necessary due to prolonged mechanical ventilation. The limited spinal mobility and proximity to the surgical site of anterior cervical spine fixation (ACSF) could pose an increased risk for complications of percutaneous dilational tracheostomy (PDT.) Importantly, PDT might raise wound infection rates of the cervical spine approach. The aim of this study is to prove safety of PDT after ACSF.
METHODS: We performed a retrospective, single-center study comparing patients with and without ACSF who underwent Ciaglia-single step PDT. After propensity score matching using logistic regression, we compared intra- and postprocedural complication rates. Furthermore, surgical site infections were evaluated. Putensen's definitions of complications and Clavien-Dindo's classification were used.
RESULTS: A total of 1175 patients underwent PDT between 2009 and 2021. Fifty-seven patients underwent PDT following ACSF and were matched to fifty-seven patients without ACSF. The mean interval between ACSF and PDT was 11.3 days. The overall complication rate was 19.3% in the ACSF group and 21.1% in the non-ACSF group. The mean follow-up was 388 days (± 791) in the ACSF group and 424 days (± 819) in the non-ACSF group. Life-threatening complications (Clavien-Dindo IV to V) were found in 1.8% of ACSF patients and 3.5% of non-ACSF patients. There were no significant differences in complication rates. No surgical site infection of the anterior spine access was detected.
CONCLUSION: PDT is a feasible and safe procedure in patients after ACSF. Complication rates are comparable to patients without ACSF. Surgical site infections of ACSF are very rare.
PURPOSE:To provide the allergy therapeutic agent not having any adverse action but having an excellent antiallergic action different from those of conven tional allergy-therapeutic agents. CONSTITUTION:This allergy therapeutic agent contains hyaluronic acid and/or its nontoxic salt such as sodium salt, potassium salt or calcium salt as an active ingredient. The therapeutic agent is especially used as a collunarium, ophthalmic agent, skin and mucous membrane-coating agent or spray-coating agent for oral cavities and pharynxes. The concentration of the active ingredient is preferably 0.01-2wt.%, 0.0001-5wt.%, 0.01-10wt.% and 0.01-10wt.% in the cases of the collunarium, the ophthalmic agent, the coating agent for the skin and mucous membrane, and the spray-coating agent for the oral cavities.pharynxes, respectively, although the concentration of the active ingredient cannot absolutely be determined, because the viscosity and fluidity of the solution is different in response to the mol.wt. of the active ingredient, and although the concentration is different by its preparation shape and its using method. Although especially not limited, the mol.wt. of the active ingredient is preferably 10000-5000000. Other allergic agents having different action mechanisms may together be used in order to enhance the allergic effect.
Patients previously randomized to Arm C (chemoradiation and durvalumab) who achieve clinical CR or clinical benefit receive durvalumab IV over 60 minutes on day 1 of each cycle. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo bladder biopsy on study, cystoscopy on study and during follow-up, as well as CT or MRI throughout the trial. Patients may also undergo tumor tissue and blood sample collection on study.
The invention relates to a medical visual question-answering method based on image information consistency verification. The method comprises the following steps: and inputting the text into a text feature extraction module to obtain text features. And performing modal identification on the medical image, inputting the image into a modal classification network in the image feature extraction module, identifying the imaging mode of the medical image and distributing a label for the imaging mode. The model learns image features on multiple scales through a multi-scale convolution module. And after the multi-scale convolution module, the context semantic information is efficiently acquired through the spatial feature extraction module. Gradient explosion and network degradation are prevented by the encoding-decoding residual connection structure. And inputting the image and text features into a multi-modal feature fusion module, and inputting the image and text features into an answer classifier to obtain a predicted answer. Experimental results show that the invention can obtain better effect on medical visual question-answering task.
BACKGROUND: Alzheimer's disease (AD) is a common chronic neurodegenerative disease in older people, and there is no specific treatment that can stop or reverse its progression. Neobavaisoflavone (NBIF) is a flavonoid that has been shown to have neuroprotective effects, but its role in AD has not been revealed. The present study investigated the role and mechanism of NBIF on Aβ25-35-induced brain injury.
METHODS: In this experiment, the AD mouse model was established by injection of Aβ25-35 peptides (200 μM, icv), and Donepezil (Don, 10 mg/kg/days), NBIF-L (15 mg/kg/days), and NBIF-H (30 mg/kg/days) were administered orally for 4 weeks. Learning memory, hippocampal pathological changes, pathological markers, apoptosis, oxidative stress, inflammation, immune cells were measured in mice. Network pharmacology combined with the GEO database led to the identification of SIRT1, a key target for NBIF intervention in AD, and levels of SIRT1, p-STAT3 and FOXO1 were measured. In addition, the antagonistic activity of SIRT1 transfection silencing against NBIF in Aβ25-35-induced in N9 cells and N2a-APP69 cells was investigated to assess whether the effects caused by NBIF were mediated by SIRT1.
RESULTS: The results showed that NBIF ameliorated learning memory and hippocampal neuronal damage, reduced pathological markers, apoptosis, oxidative stress and neuroinflammation, and modulated immune cells. SIRT1 is a key target for NBIF intervention in AD, and NBIF upregulates SIRT1 and reduces the expression levels of p-STAT3 and FOXO1. Furthermore, silencing SIRT1 effectively reduced the protective effect of NBIF on Aβ25-35-induced N9 cells and N2a-APP69 cells, which indicated that the protective effect of NBIF on AD is related to SIRT1.
CONCLUSIONS: NBIF ameliorated Aβ25-35-induced brain injury by inhibiting apoptosis, oxidative stress, and neuroinflammation, which may be mediated through SIRT1 signaling. These findings provide a rationale for NBIF in the treatment of AD and help facilitate the development of clinical therapeutic agents for AD.
The invention provides a transgenic non-human animal having a functional disruption in an endogenous SLPI gene. According to the invention, the disruption results in impaired wound healing, reduced defense to pathogens, pathogenic response to antigen induced asthma, or a pathogenic inflammatory response. The invention also provides methods for making the transgenic non-human animal. The transgenic non-human animal can be used as a model for disease states including inflammation, for example, asthma, wound healing, etc. and to screen for therapeutic agents for treating the same. The invention also provides a method for treating inflammation, by administering SLPI peptide.